Which of the following is the first-line pharmacological agent for maintenance therapy in stable COPD with FEV₁ 40–60% predicted?

Explanation

## First-Line Maintenance Therapy in COPD **Key Point:** For stable COPD with FEV₁ 40–60% predicted (GOLD Group B), long-acting muscarinic antagonists (LAMA) or long-acting beta-2 agonists (LABA) are preferred as monotherapy, with LAMA often preferred due to superior mortality benefit in some populations and lower exacerbation rates. **High-Yield:** The GOLD 2023 guidelines recommend LAMA or LABA monotherapy as first-line for symptomatic patients in Group B (moderate airflow obstruction). LAMA agents (tiotropium, glycopyrronium, umeclidinium) are increasingly favored because: - Reduce exacerbation frequency - Improve lung function and symptom control - Better mortality benefit compared to LABA alone in some trials - Anticholinergic mechanism provides sustained bronchodilation **Clinical Pearl:** The choice between LAMA and LABA depends on symptom predominance: LAMA preferred for obstruction-predominant symptoms; LABA preferred if dyspnea on exertion is the main complaint. However, LAMA is now the preferred initial monotherapy in most guidelines. **Mnemonic:** **LAMA First** — Long-Acting Muscarinic Antagonist is the modern first-line for moderate COPD. ## Why Not the Others? | Agent | Role in COPD | Limitation | | --- | --- | --- | | LABA monotherapy | Alternative first-line, but inferior to LAMA | Increased mortality risk if used alone in some populations; requires monitoring | | ICS monotherapy | Reserved for asthma-COPD overlap or frequent exacerbations | Increases infection risk (oral candidiasis, pneumonia); not first-line for pure COPD | | Roflumilast | Add-on for frequent exacerbators | Not a first-line agent; reserved for patients with chronic bronchitis phenotype and recurrent exacerbations | ## Treatment Algorithm ```mermaid flowchart TD A[Stable COPD diagnosed]:::outcome --> B{FEV₁ and symptoms?}:::decision B -->|FEV₁ 40-60%, symptomatic| C[LAMA or LABA monotherapy]:::action B -->|FEV₁ <40%, symptomatic| D[LAMA + LABA ± ICS]:::action B -->|Frequent exacerbations| E[Add roflumilast or macrolide]:::action C --> F[Reassess at 4 weeks]:::decision F -->|Improved| G[Continue monotherapy]:::action F -->|Inadequate response| H[Escalate to dual therapy]:::action ``` [cite:Harrison 21e Ch 254]